Joint Clinical Trials Office
A Phase 3b, open label, randomized, standard-of-care control arm, multicenter, superiority study evaluating the efficacy, safety and tolerability of injectable CAB LA + RPV LA in viremic participants living with HIV-1 (CROWN)
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 13, 2025
A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants with Chronic HDV Infection (ECLIPSE 1)
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 19, 2025
A Prospective Multi-Center, Single-Arm Study of Endoscopic Ultrasound-Guided Gastroenterostomy with Lumen-Apposing Metal Stent for Gastric Outlet Obstruction from Malignant Unresectable Disease
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 19, 2025
A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of BHV-1510 (Previously PBI-410) as Monotherapy and in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 19, 2025
A Randomized, Phase III Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First-line Treatment of HER2-positive Gastric Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 19, 2025
Genetic Developmental and Epileptic Encephalopathy Natural History Study for Clinical Trial Readiness
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 9, 2025
Alzheimer's Network for Treatment and Diagnostics (ALZ-NET)
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 30, 2025
A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer’s Disease (BENFO-TEAM)
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 30, 2025
Phase II Study of Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 30, 2025
A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination with Anti-PD-1 in Advanced Solid Tum
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 30, 2025